{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:45:17Z","timestamp":1771263917768,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Boston Scientific Corporation to the University of Rochester"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Patients with impaired renal function were shown to have an attenuated benefit from implantable cardioverter-defibrillator. However, there are limited data on the competing risk of ventricular arrhythmia events and death by renal function in patients without severe disease. Therefore, we aimed to assess the competing risk of ventricular arrhythmia events and death by renal function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We analysed 1782 patients (99%) enrolled in Multicenter Automatic Defibrillator Implantation Trial\u2013Cardiac Resynchronization Therapy (MADIT\u2013CRT) with glomerular filtration rate (GFR) data available. Cumulative incidence function curves were used to display the rate of ventricular tachycardia (VT), ventricular fibrillation (VF), and the competing risk of death without experiencing VT\/VF. Multivariable Fine and Gray regression models and recurrent event analysis were performed. There were 355 (20%) patients with GFR\u2009&amp;lt;\u200952 and 1427 with GFR\u2009\u2265\u200952 (lowest quintile). The incidence of non-fatal VT\/VF at 4\u2009years was higher in patients with high GFR (26%) as compared to low GFR (16%), whereas rates of death without non-fatal VT\/VF were 5% and 20% (P\u2009&amp;lt;\u20090.001). In Fine and Gray models, the low GFR group was 35% less likely to experience VT\/VF compared to the high GFR [95% confidence interval (CI) 0.48\u20130.88, P\u2009=\u20090.005]. In contrast,death without experiencing VT\/VF was 3.5-fold higher in the low GFR group (95% CI 2.38\u20135.12, P-value\u2009&amp;lt;\u20090.001). Recurrent event analysis consistently showed a lower risk of recurrent VT\/VF, recurrent anti-tachycardia pacing only, and shock in the low GFR group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We show, in a competing risk model, a lower risk of VT\/VF events and a higher risk of mortality without an arrhythmic event in patients with moderate renal dysfunction in MADIT\u2013CRT. These findings can be used for improved selection of patients for defibrillator therapy among CRT candidates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trial Registration<\/jats:title>\n                  <jats:p>https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00180271.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euaa146","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T19:42:07Z","timestamp":1592854927000},"page":"1384-1390","source":"Crossref","is-referenced-by-count":9,"title":["Competing risk analysis of ventricular arrhythmia events in heart failure patients with moderately compromised renal dysfunction"],"prefix":"10.1093","volume":"22","author":[{"given":"Ido","family":"Goldenberg","sequence":"first","affiliation":[{"name":"Department of Medicine, Clinical Cardiovascular Research Center, Cardiology Division, University of Rochester School of Medicine and Dentistry, 265 Crittenden Blvd., PO Box 653, Rochester, NY 14642, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arwa","family":"Younis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Clinical Cardiovascular Research Center, Cardiology Division, University of Rochester School of Medicine and Dentistry, 265 Crittenden Blvd., PO Box 653, Rochester, NY 14642, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet K","family":"Aktas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Clinical Cardiovascular Research Center, Cardiology Division, University of Rochester School of Medicine and Dentistry, 265 Crittenden Blvd., PO Box 653, Rochester, NY 14642, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"McNitt","sequence":"additional","affiliation":[{"name":"Department of Medicine, Clinical Cardiovascular Research Center, Cardiology Division, University of Rochester School of Medicine and Dentistry, 265 Crittenden Blvd., PO Box 653, Rochester, NY 14642, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Zareba","sequence":"additional","affiliation":[{"name":"Department of Medicine, Clinical Cardiovascular Research Center, Cardiology Division, University of Rochester School of Medicine and Dentistry, 265 Crittenden Blvd., PO Box 653, Rochester, NY 14642, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-289X","authenticated-orcid":false,"given":"Valentina","family":"Kutyifa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Clinical Cardiovascular Research Center, Cardiology Division, University of Rochester School of Medicine and Dentistry, 265 Crittenden Blvd., PO Box 653, Rochester, NY 14642, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"2020101222144000800_euaa146-B1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1540-8159.2007.00651.x","article-title":"Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death","volume":"30","author":"Cuculich","year":"2007","journal-title":"Pacing Clin Electro"},{"key":"2020101222144000800_euaa146-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2020101222144000800_euaa146-B3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/CIRCULATIONAHA.105.580506","article-title":"Renal function as a predictor of outcome in a broad spectrum of patients withheart failure","volume":"113","author":"Hillege","year":"2006","journal-title":"Circulation"},{"key":"2020101222144000800_euaa146-B4","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCEP.114.002109","article-title":"Defibrillator therapy in chronic kidney disease is it worth it?","volume":"7","author":"Patton","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2020101222144000800_euaa146-B5","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1001\/jama.292.23.2874","article-title":"Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy","volume":"292","author":"Desai","year":"2004","journal-title":"JAMA"},{"key":"2020101222144000800_euaa146-B6","first-page":"809","article-title":"Implantable cardioverter-defibrillators: expanding indications and technologies","volume":"295","author":"Goldberger"},{"key":"2020101222144000800_euaa146-B7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-147-4-200708210-00007","article-title":"Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction","volume":"147","author":"Ezekowitz","year":"2007","journal-title":"Ann Intern Med"},{"key":"2020101222144000800_euaa146-B8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1161\/CIRCEP.114.001455","article-title":"Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease","volume":"7","author":"Hess","year":"2014","journal-title":"Circ Arrhythmia Electrophysiol"},{"key":"2020101222144000800_euaa146-B9","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/jce.12435","article-title":"Chronic kidney disease and implantable cardioverter defibrillator related complications: 16 years of experience","volume":"25","author":"Buiten","year":"2014","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2020101222144000800_euaa146-B10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/europace\/euy305","article-title":"Risk of death without appropriate defibrillator shock in patients with advanced renal dysfunction","volume":"21","author":"Goldenberg","year":"2019","journal-title":"Europace"},{"key":"2020101222144000800_euaa146-B11","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1016\/j.jacc.2015.09.097","article-title":"Comparative effectiveness of CRT-D versus defibrillator alone in HF patients with moderate-to-severe chronic kidney disease","volume":"66","author":"Friedman","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2020101222144000800_euaa146-B12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/pace.13659","article-title":"Renal function and the long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation","volume":"42","author":"Leyva","year":"2019","journal-title":"Pacing Clin Electrophysiol"},{"key":"2020101222144000800_euaa146-B13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamainternmed.2017.8462","article-title":"Long-term outcomes associated with implantable cardioverter defibrillator in adults with chronic kidney disease","volume":"178","author":"Bansal","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2020101222144000800_euaa146-B14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/eurheartj\/ehq403","article-title":"Renal function and mortality following cardiac resynchronization therapy","volume":"32","author":"Lin","year":"2011","journal-title":"Eur Heart J"},{"key":"2020101222144000800_euaa146-B15","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1161\/CIRCULATIONAHA.107.742155","article-title":"Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study","volume":"117","author":"Koller","year":"2008","journal-title":"Circulation"},{"key":"2020101222144000800_euaa146-B16","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"2020101222144000800_euaa146-B17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2020101222144000800_euaa146-B18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/B:JICE.0000048570.43706.34","article-title":"Impact of chronic kidney disease upon survival among implantable cardioverter-defibrillator recipients","volume":"11","author":"Wase","year":"2004","journal-title":"J Interv Card Electrophysiol"},{"key":"2020101222144000800_euaa146-B19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ahj.2005.06.042","article-title":"Renal insufficiency predicts the time to first appropriate defibrillator shock","volume":"151","author":"Hreybe","year":"2006","journal-title":"Am Heart J"},{"key":"2020101222144000800_euaa146-B20","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJM199212313272704","article-title":"Sympathetic overactivity in patients with chronic renal failure","volume":"327","author":"Converse","year":"1992","journal-title":"N Engl J Med"},{"key":"2020101222144000800_euaa146-B21","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/ehz260","article-title":"Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study","volume":"40","author":"Gatzoulis","year":"2019","journal-title":"Eur Heart J"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/europace\/article-pdf\/22\/9\/1384\/33867054\/euaa146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/europace\/article-pdf\/22\/9\/1384\/33867054\/euaa146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T02:14:54Z","timestamp":1602555294000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/22\/9\/1384\/5900351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,1]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euaa146","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,9,1]]}}}